Peptides9 min read
Oxytocin and autism: what the larger trials changed
Small positive studies led to larger trials that tempered the treatment claim. Outcomes, subgroups, and meaningful goals all matter.
Read articleBlog
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides8 min read
The 2026 DSIP debate: what the FDA discussion can tell you about sleep
The FDA's 2026 emideltide discussion concerned compounding ingredients and evidence gaps, not a new demonstration that DSIP treats insomnia.
Read article
Peptides9 min read
Afamelanotide for EPP: a treatment for painful light sensitivity
Afamelanotide can improve painful light sensitivity in EPP. Learn what the trials measured, their limitations and why the findings do not endorse tanning products.
Read article
Peptides9 min read
Afamelanotide and skin checks: why pigment changes need context
Afamelanotide can darken existing moles. Learn why regular full-body skin checks, earlier review of changes and a useful treatment history matter.
Read article
Peptides8 min read
A diabetic cat can look well while glucose runs low: a glargine pilot's lesson
A calm, comfortable cat can still have a low glucose reading. A small glargine U-300 study shows why symptoms, glucose curves and longer-term markers belong together.
Read article
Peptides9 min read
Can topical GHK-Cu evidence support injectable GHK-Cu claims?
Topical GHK-Cu research cannot establish an injectable treatment. See why route, copper measurements, formulation, and safety evidence must stay separate.
Read article
Peptides8 min read
Tirzepatide and fatty liver: what a biopsy result means
What tirzepatide's liver-biopsy results show about MASH activity and scarring, and why neither endpoint proves prevention of liver failure.
Read article
Peptides8 min read
What mazdutide's Chinese phase 3 trial actually establishes
GLORY-1 showed weight reduction beyond placebo. Its population, endpoints, analysis methods and tolerability define the result's clinical meaning.
Read article
Peptides9 min read
Oxytocin and appetite: what meal studies tell us about weight loss
Human studies separate short-term changes in eating from sustained weight loss, with different findings across populations and routes.
Read article
Peptides8 min read
Mazdutide approval: what an overseas decision means where you live
China's mazdutide approval concerns a defined product and use. Local access, product identity, importation and athlete eligibility require separate checks.
Read article
Peptides9 min read
Eloralintide weight loss: who was studied changes what the result means
The headline weight-loss result came from a specific population. Age, diabetes status, eligibility and the analysis all affect its relevance.
Read article
Peptides8 min read
Zenagamtide tolerability: how many people could stay on treatment?
Stopping zenagamtide, withdrawing from a study and reporting an adverse event are different outcomes. The trial protocols explain why that matters.
Read article37–48 of 320 articles